PMID- 28478443
OWN - NLM
STAT- MEDLINE
DCOM- 20171218
LR  - 20181202
IS  - 1421-9875 (Electronic)
IS  - 0257-2753 (Linking)
VI  - 35
IP  - 5
DP  - 2017
TI  - Immunosuppressive Agents for the Treatment of Primary Sclerosing Cholangitis: A 
      Systematic Review and Meta-Analysis.
PG  - 478-485
LID - 10.1159/000471874 [doi]
AB  - OBJECTIVES: Currently, there are no effective therapeutic agents for patients 
      with primary sclerosing cholangitis (PSC). This study aimed to evaluate the 
      safety and efficiency of immunosuppressive agents (IAs) for the treatment of PSC. 
      METHODS: The literatures were searched using the following keywords singly or in 
      combination: PSC, treatments, IAs. The primary outcome was defined as the need 
      for liver transplantation or mortality. RESULTS: Two hundred sixty six patients 
      from 7 eligible studies were analyzed. IAs had no remarkable effects on the rate 
      of mortality or liver transplantation (relative risk, RR 1.02, 95% CI 0.58-1.62, 
      p = 0.92). Subgroup analyses showed no significant effect of IAs 
      co-administration therapy (IAs co-administered with ursodeoxycholic acid, IA 
      co-administered with IA; RR 1.41, 95% CI 0.40-4.95, p = 0.60). IAs caused adverse 
      events (AEs) such as diarrhea, abdominal pain, and pruritus (RR 1.81, 95% CI 
      1.07-3.07, p = 0.03). IAs therapy did not significantly improve markers of liver 
      function except for aspartate transaminase (weighted mean difference -9.76, 95% 
      CI -12.92 to -6.6, p < 0.001). CONCLUSION: IAs administrated as either 
      monotherapy or combination therapy do not reduce the risk of mortality or liver 
      transplantation. IAs monotherapy is associated with AEs.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Peng, Xia
AU  - Peng X
AD  - Department of Gastroenterology, Sun Yat-sen Memorial Hospital, Guangzhou, China.
FAU - Luo, Xin
AU  - Luo X
FAU - Hou, Jing-Ying
AU  - Hou JY
FAU - Wu, Shu-Yun
AU  - Wu SY
FAU - Li, Liang-Zong
AU  - Li LZ
FAU - Zheng, Ming-Hua
AU  - Zheng MH
FAU - Wang, Ling-Yun
AU  - Wang LY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170506
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Cholangitis, Sclerosing/*drug therapy
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Liver/pathology
MH  - Publication Bias
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Immunosuppressive agents
OT  - Meta-analysis
OT  - Primary sclerosing cholangitis
EDAT- 2017/05/10 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/05/08 06:00
PHST- 2016/12/14 00:00 [received]
PHST- 2017/03/21 00:00 [accepted]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/05/08 06:00 [entrez]
AID - 000471874 [pii]
AID - 10.1159/000471874 [doi]
PST - ppublish
SO  - Dig Dis. 2017;35(5):478-485. doi: 10.1159/000471874. Epub 2017 May 6.